Confronto
Oxytocin vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
50-56-6
396091-73-9
Peso molecolare
1007.19 g/mol
1047.21 g/mol
Emivita
0.05 h
nessun dato
Sequenza
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2nessun dato
Meccanismo d'azione
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
0
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Oxytocin and Pasireotid?
- Oxytocin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Oxytocin or Pasireotid?
- The highest available evidence level is "RCT sull'uomo" for Oxytocin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Oxytocin and Pasireotid in Germany and the United States?
- Germania: Oxytocin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Oxytocin — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.